Alizadeh Ali Akbar, Jafari Behzad, Dastmalchi Siavoush
Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Medicinal Chemistry, School of Pharmacy, Urmia University of Medical Sciences, Iran.
J Mol Graph Model. 2020 Jan;94:107459. doi: 10.1016/j.jmgm.2019.107459. Epub 2019 Sep 29.
Sphingosine 1-phosphate type 1 (S1P) receptors are expressed on lymphocytes and regulate immune cells trafficking. Sphingosine 1-phosphate and its analogues cause internalization and degradation of S1P receptors, preventing the auto reactivity of immune cells in the target tissues. It has been shown that S1P receptor agonists such as fingolimod can be suitable candidates for treatment of autoimmune diseases. The current study aimed to generate GRIND-based 3D-QSAR predictive models for agonistic activities of 2-imino-thiazolidin-4-one derivatives on S1P to be used in virtual screening of chemical libraries. The developed model for the S1P receptor agonists showed appropriate power of predictivity in internal (r 0.93 and SDEC 0.18) and external (r 0.75 and MAE (95% data), 0.28) validations. The generated model revealed the importance of variables DRY-N1 and DRY-O in the potency and selectivity of these compounds towards S1P receptor. To propose potential chemical entities with S1P agonistic activity, PubChem chemicals database was searched and the selected compounds were virtually tested for S1P receptor agonistic activity using the generated models, which resulted in four potential compounds with high potency and selectivity towards S1P receptor. Moreover, the affinities of the identified compounds towards S1P receptor were evaluated using molecular dynamics simulations. The results indicated that the binding energies of the compounds were in the range of -39.31 to -46.18 and -3.20 to -9.75 kcal mol, calculated by MM-GBSA and MM-PBSA algorithms, respectively. The findings in the current work may be useful for the identification of potent and selective S1P receptor agonists with potential use in diseases such as multiple sclerosis.
1-磷酸鞘氨醇1型(S1P)受体在淋巴细胞上表达,并调节免疫细胞的迁移。1-磷酸鞘氨醇及其类似物会导致S1P受体的内化和降解,从而防止免疫细胞在靶组织中发生自身反应。研究表明,像芬戈莫德这样的S1P受体激动剂可能是治疗自身免疫性疾病的合适候选药物。当前的研究旨在生成基于GRIND的三维定量构效关系(3D-QSAR)预测模型,用于预测2-亚氨基噻唑烷-4-酮衍生物对S1P的激动活性,以用于化学文库的虚拟筛选。所开发的S1P受体激动剂模型在内部验证(r = 0.93,标准偏差估计值(SDEC)= 0.18)和外部验证(r = 0.75,平均绝对误差(MAE,95%数据)= 0.28)中显示出适当的预测能力。生成的模型揭示了变量DRY-N1和DRY-O在这些化合物对S1P受体的效力和选择性方面的重要性。为了提出具有S1P激动活性的潜在化学实体,搜索了PubChem化学数据库,并使用生成的模型对所选化合物进行了S1P受体激动活性的虚拟测试,结果得到了四种对S1P受体具有高效力和选择性的潜在化合物。此外,使用分子动力学模拟评估了所鉴定化合物对S1P受体的亲和力。结果表明,分别通过MM-GBSA和MM-PBSA算法计算,这些化合物的结合能在-39.31至-46.18千卡/摩尔和-3.20至-9.75千卡/摩尔范围内。当前工作的研究结果可能有助于识别具有高效力和选择性的S1P受体激动剂,这些激动剂在诸如多发性硬化症等疾病中可能具有潜在用途。